SCHEMBL30775196

SCHEMBL30775196

Cc1cnccc1-c1cccc2c1CNC2=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 4/20 0.49
ROCK1 Q13464 4/20 0.49
PIM1 P11309 3/20 0.49
CDK5 Q00535 2/20 0.49
DYRK1A Q13627 2/20 0.49
CSNK1A1 P48729 1/20 0.49
LRRK2 Q5S007 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
KDR P35968 11/20 0.48
ROCK2 O75116 3/20 0.48
MAP4K4 O95819 3/20 0.48
LCK P06239 3/20 0.48
RET P07949 3/20 0.48
RPS6KB1 P23443 3/20 0.48
BLK P51451 3/20 0.48
STK3 Q13188 3/20 0.48
TAOK1 Q7L7X3 3/20 0.48
HIPK4 Q8NE63 3/20 0.48
AURKB Q96GD4 3/20 0.48
MKNK2 Q9HBH9 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775244 0.82 PARP10 (0.57) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30775381 0.82 CLK4 (0.49) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30775271 0.78 CLK4 (0.45) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30775238 0.77 PDE3B (0.49) CLK4ROCK1PIM1NTRK1CSF1R
SCHEMBL9475196 0.77 PARP1 (0.68) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30331787 0.77 PARP1 (0.68) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL29845432 0.76 CLK4 (0.57) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30775313 0.75 CLK4 (0.53) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30190467 0.75 CLK4 (0.51) CLK4ROCK1PIM1CDK5DYRK1A
SCHEMBL30775186 0.75 PARP10 (0.56) CLK4ROCK1PIM1CDK5DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR CLK4 3903/4885ROCK1 1533/4885PIM1 4064/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR CLK4 3903/4885ROCK1 1533/4885PIM1 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.